An antibody raised against guanylate cyclase soluble subunit alpha-2 (GUCYA2); GUCYA2 is a negative regulator of guanylyl cyclase activity.
Catalogue number crb2005742 Antibody Anti-GUCY1A2 antibody Antigen Peptide KLH conjugated synthetic peptide crb1200951 Protein ID UniProtKB - P33402 (Human) Aliases GCS-alpha-2, GUC1A2, GUCSA2, Guanylate cyclase soluble subunit alpha-2 Cross-Reactivity Human Host Species Rabbit Antibody Type Polyclonal Concentration 1.0 mg/ml Glycine Target GUCY1A2 Family Adenylyl cyclase class-4/guanylyl cyclase family Storage This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/thaw cycles. References
Li et al., (2021). Overexpression of GUCY1A2 correlates with poor prognosis in gastric cancer patients. Front. Oncol., 11: 1977. doi: 10.3389/fonc.2021.632172.
Rotimi et al., (2019). Gene expression profiling analysis reveals putative phytochemotherapeutic target for castration-resistant prostate cancer. Front. Oncol., 9: 714. doi: 10.3389/fonc.2019.00714.
Soluble guanylate cyclases (sGCs) are heterodimeric enzymes that convert GTP to 3′,5′-cyclic GMP and pyrophosphate. Most complexes consist of an alpha subunit, such as alpha-2 (GUCY1A2), and a beta subunit, typically beta-1 (GUCY1B3). In the presence of magnesium or manganese ions, enzyme activity is stimulated by nitric oxide.
sGCs are the principal receptors for nitric oxide (NO) and NO-releasing drugs. sGC plays a role in several cardiovascular pathways. Diminished sGC function contributes to several conditions, including cardiovascular diseases. sGC-induced cGMP increase ultimately affects vascular relaxation, inhibition of platelet aggregation, and altered neurotransmission.
sGC GUCY1A2 is upregulated in several cancers and promotes tumorigenesis. GUCY1A2 regulation is particularly dysregulated in cervical, prostate, and gastric cancer. The expression of GUCY1A2 is being proposed as a prognostic indicator for the outcome of gastric cancer and prostate cancer.